AConfirm Virologic Cure
Follow-up HCV RNA testing is used to determine whether the virus remains undetectable after treatment.
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). It can cause short-term infection or persist as chronic infection, and chronic hepatitis C can progressively damage the liver if it is not diagnosed and treated.
Many people with hepatitis C have few or no symptoms, particularly in the earlier stages. This means a person may have an HCV infection without knowing it.
Persistent HCV infection can cause ongoing liver inflammation and damage. In some patients, this can progress to fibrosis, cirrhosis or liver cancer
Modern direct-acting antiviral medicines can cure hepatitis C in most people. Treatment selection depends on the patient’s HCV status, liver condition, previous treatment and other relevant clinical factors.
Hepatitis C is primarily transmitted when blood containing HCV enters another person's bloodstream. Understanding the route of exposure helps identify people who may benefit from testing.
HCV can spread through exposure to infected blood.
Sharing contaminated needles or equipment can transmit HCV. Appropriate infection-control practices reduce healthcare-associated transmission.
People with a history of certain blood or medical exposures may be advised to undergo hepatitis C testing.
HCV can also be transmitted through certain other blood exposures. Individual risk assessment should be based on the patient's history.
Hepatitis C often causes no noticeable symptoms, especially early in the infection. When symptoms occur, they may include fatigue, nausea, loss of appetite, abdominal discomfort, dark urine, pale stools or jaundice.
Fatigue can occur with hepatitis C and other liver conditions.
Some people may experience reduced appetite, nausea or general digestive discomfort.
Some patients may experience discomfort in the upper abdomen.
Changes in urine or stool colour can occur when liver function or bilirubin handling is affected.
Yellowing of the skin or whites of the eyes can occur when bilirubin builds up.
A person can have active hepatitis C without obvious symptoms, so testing is important when exposure or other clinical indications are present.
Untreated chronic hepatitis C can cause progressive liver damage. The risk of complications depends on the duration of infection, the extent of liver injury and other patient-specific factors.
Long-term inflammation can lead to increasing liver scarring.
Advanced scarring can impair liver function and increase the risk of complications.
Severe advanced liver disease can result in significant loss of liver function.
Chronic hepatitis C, particularly when cirrhosis is present, is associated with an increased risk of hepatocellular carcinoma.
Advanced cirrhosis can lead to increased portal pressure and complications such as variceal bleeding and ascites.
Advanced liver disease may be associated with dysfunction of other organs and requires specialist monitoring.
The testing pathway distinguishes previous exposure from active infection and helps the liver team understand whether treatment is required and whether liver damage is already present.
Hepatitis C is treated primarily with oral direct-acting antiviral (DAA) medicines. Modern treatment can cure most patients, with the specific regimen and duration selected according to the patient’s HCV status, liver condition, previous treatment and other clinical factors.
Confirm that HCV infection is currently active using the appropriate testing pathway.
Evaluate liver health and determine whether fibrosis, cirrhosis or other liver complications are present.
Choose an appropriate direct-acting antiviral regimen based on the patient’s clinical circumstances.
Take the prescribed antiviral medicines for the recommended duration and attend follow-up as advised.
Post-treatment HCV RNA assessment is used to establish sustained virologic response and virologic cure.
Patients with established cirrhosis or other residual liver disease may require continued follow-up even after HCV cure.
The goal of treatment is sustained virologic response, meaning that HCV RNA is no longer detectable at the appropriate post-treatment assessment. If cirrhosis or significant liver disease was present before cure, ongoing liver follow-up may still be required.
Follow-up HCV RNA testing is used to determine whether the virus remains undetectable after treatment.
Curing hepatitis C does not necessarily reverse established cirrhosis. Patients with cirrhosis may continue to need liver monitoring and surveillance for complications, including liver cancer.
Successful treatment does not create protective immunity. A person can acquire hepatitis C again after a new exposure.
Follow-up based on liver stage; surveillance when cirrhosis is present; management of other liver conditions; review of alcohol and other liver-health risks; prevention of future HCV exposure.
Hepatitis C can become clinically more complex when chronic infection has already caused significant fibrosis, cirrhosis, liver cancer or complications of advanced liver disease. These patients may require coordinated hepatology, gastroenterology, transplant surgery and supportive care.
Patients with advanced liver disease may develop complications such as ascites, gastrointestinal bleeding, jaundice, hepatic encephalopathy or kidney dysfunction.
Patients with chronic liver disease may require appropriate surveillance and specialist evaluation when liver cancer is suspected or diagnosed.
For patients who already have advanced liver disease, treatment of HCV is only one part of care. The liver team may also need to manage complications and assess whether additional advanced liver-care pathways are required.
Managing complications of advanced liver disease; closer specialist monitoring; nutritional and supportive care; liver cancer surveillance when appropriate; assessment for advanced liver-care pathways.
Most people with hepatitis C do not require a liver transplant. Antiviral treatment can cure the infection in most patients. Transplant evaluation becomes relevant when chronic hepatitis C has already caused advanced or decompensated liver disease, liver failure or other transplant-related indications..
Transplant evaluation may be considered when liver function is significantly impaired or complications become difficult to control.
Repeated or severe complications of advanced liver disease may require assessment for advanced treatment options.
The transplant team evaluates liver disease severity together with overall health and other relevant medical factors.
Where transplantation is appropriate, patients may be evaluated through living-donor or deceased-donor pathways subject to medical, legal and allocation requirements.
Liver transplantation is considered for selected patients whose chronic hepatitis C has resulted in advanced liver disease, liver failure or other transplant indications. The decision is individualised and depends on liver function, complications, overall health and transplant eligibility.
Significant loss of liver function may lead to transplant evaluation.
Complications such as recurrent ascites, variceal bleeding or hepatic encephalopathy may indicate advanced disease requiring specialist assessment.
Some patients with liver cancer may be evaluated for transplantation depending on tumour characteristics and established transplant criteria.
MBBS · DNB (General Surgery) · Fellowship in Liver Transplantation, Global Hospital, Chennai
Dr. Manoj Shrivastav is a liver transplant surgeon at Ruby Hall Clinic, Pune, and currently leads the multi-organ transplant programme. He has personally completed over 200 liver transplants in Pune, 100 of them in the past year alone, with a survival rate above 95% and a one-year survival rate of 92% across his transplant series.
He is equipped to handle acute surgical emergencies and trauma across a variety of scenarios, has performed major liver resections for hepatocellular carcinoma and cholangiocarcinoma, and believes a successful transplant depends on excellent teamwork across the entire clinical team — not one surgeon alone.
Meet the TeamYes. Modern direct-acting antiviral medicines can cure hepatitis C in most people. The exact treatment and outcome depend on individual clinical factors.
Many modern oral DAA treatment courses are short and commonly last around 8–12 weeks, although the appropriate regimen and duration depend on the patient’s clinical circumstances.
No. A reactive antibody test indicates previous exposure to HCV. HCV RNA testing is used to determine whether there is current active infection.
Chronic untreated hepatitis C can cause progressive liver damage and may eventually lead to cirrhosis and liver cancer.
There is currently no vaccine that prevents hepatitis C. Prevention therefore focuses on avoiding exposure to infected blood.
Yes. Successful treatment does not create protective immunity, so reinfection is possible after a new exposure.
Yes. If cirrhosis is present, ongoing liver follow-up and appropriate surveillance may still be required even after HCV infection has been cured.
Bring your HCV antibody/RNA reports, liver tests, scans and current medication list to your consultation.